Artifacts in Nuclear Medicine with Identifying and resolving artifacts.
Validation of candidate biomarker proteins for the early detection of lung cancer
1.
2. The 5-year survival rate improves from 16% overall to 70-90% when the disease is diagnosed and treated at an early stage.
3. Early detection is a promising strategy to reducemortality, however the current technologies are neither practical nor cost effective for screening the general population.
4. A blood based biomarker would be ideal since blood is easily accessible and measurements can be readily repeated over time without invasive procedures.
5. The field has incredible room for growth and with the use of proteomics, suitable biomarkers can be identified and validated. Some methods commonly used in the validation include: Western Blot, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemical staining and Mass Spectrometry.
6.
7. From our preliminary results we can conclude that DKK1 is overexpressed in lung cancer. A cut off value of 0.4 ng/mLidentified 9tumors with elevated values out of the 20 sampled.
8. The later stages of lung cancer correlated to higher plasma concentrations of DKK1. Preliminary data did not suggest a correlation between concentration of DKK1 with the patient’s age, smoking status or gender in our dataset. Table 2. Characteristics of the patient plasma samples Fig.2 Flow chart illustrating the improved selection process of the candidates Fig.3 Flow chart illustrating the validation process of the biomarker candidates Future Work This project will continue to validate selected biomarkers and investigate the utility of novel biomarkers. Potential to multiplex the assay will also be explored. Where the usual methods of validation, such as ELISA are not available, the biomarker’s potential will be investigated through the development of other methods such as radioimmunoassay or MS-based approaches. Acknowledgements Vanderbilt University – Office of Biomedical Research Education and Training (BRET) Summer Science Academy - Undergraduate Clinical Research Internship Program (UCRIP) The Massion Lab Group : Vanderbilt-Ingram Cancer Center
![Validation of candidate biomarker proteins for the early detection of lung cancer Monique Simpson, JamshedurRahman, Peter Coulson, RonakShah, John ShaughnessyJrand Pierre Massion Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt-Ingram Cancer Center, Nashville, TN. Veterans Affairs Medical Center, Nashville, TN. Introduction Results Results Data obtained using ELISA for the detection of DKK1 concentration in plasma samples confirms that DKK1 is a strong candidate biomarker for the detection of lung cancer. ,[object Object]](https://image.slidesharecdn.com/bret20monique20simpson20poster20july2020091-124871460695-phpapp02/85/validation-of-candidate-biomarker-proteins-for-the-early-detection-of-lung-cancer-1-320.jpg)
